亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國CardioMEMS
CardioMEMS是一個醫療器械公司已開發并正在商業化專有無線傳感和人體通信技術。我們的技術平臺，目的是改善諸如動脈瘤，心臟衰竭，高血壓，嚴重慢性心血管疾病的管理。我們的微型無線傳感器可以植入用微創技術和傳輸心輸出量，血壓和心率數據，是至關重要的病人管理。我們的傳感器被設計成永久性心臟和血管由于其體積小，耐用性植入，以及電線和電池不足。利用射頻或RF，能源，我們的傳感器傳送實時數據外部電子閱讀器，然后傳達這一信息對病人的醫生。我們相信頻繁，點播，重要信息的實時監測病人能夠主動管理，持有減少住院的承諾，改善病人的生活質量和提供更有效率和成本效益的醫療。
所作的發言，本新聞稿中期待在時間或表達信念，預期或對未來的希望或預期出現的結果都是前瞻性聲明。阿如產品開發和商業化的努力預計何時或任何臨床試驗，最終的臨床結果和知覺或本公司的產品，市場和醫生的產品，知識產權保護驗收的實際優勢的結果，可能帶來的風險的風險和不確定性和競爭產品可能導致實際事件產生不利不同的期望表示在這些前瞻性聲明。
CardioMEMS是CardioMEMS，公司的注冊商標

美國CardioMEMS公司最近成功融資兩千兩百一十萬美元，用于重要的臨床試驗。CardioMEMS正在開發一種能夠植入人體來控制心力衰竭、動脈瘤、高血壓等嚴重的慢性心血管疾病的無線器件。以上投資來自公司現有的投資者，包括Arcapita Ventures、Boston Millennia Partners、 Foundation Medical Partners，是其計劃的二千九百五十五萬元融資的一部分。

資金將用于CHAMPION臨床試驗，評估CardioMEMS心力衰竭壓力監控系統。臨床試驗將在美國的65個心血管中心進行。

CardioMEMS的心力衰竭傳感器是一個微型器件，將用導管的方式植入肺動脈。肺動脈的壓力則利用公司的專利電子監控系統測量并顯示。遵照程序，病人在家里無線監測其肺動脈壓力，數據立即傳送到安全的數據庫，供醫生通過CardioMEMS的網站實時監測。

CardioMEMS預期在2010年尋求FDA對其CHAMPION心力衰竭傳感器的認證。

在2007年，CardioMEMS融資三千三百萬美元。

CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients. Due to their small size, durability, and lack of wires and batteries, our sensors are designed to be permanently implanted into the cardiovascular system. Using radiofrequency, or RF, energy, our sensors transmit real-time data to an external electronics module, which then communicates this information to the patient’s physician.

Our first commercial device, the EndoSure? Wireless AAA Pressure Measurement System, is comprised of an implanted sensor and an external electronics module. The EndoSure? sensor is inserted during the minimally invasive endovascular repair of abdominal aortic aneurysms, or AAA, via a catheter into a patient’s aneurysm sac and measures and communicates pressure information to an external electronics module from inside the sac. We are adapting the technology used for our EndoSure? system for use in patients with heart failure and in patients with hypertension. Our heart failure and hypertension sensors will be further miniaturized versions of the EndoSure? sensor that use the same materials, manufacturing methods and operational concepts as the EndoSure? sensor.